Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CBMG expansion to boost clinical trial capacity
May 2017
SHARING OPTIONS:

SHANGHAI, China & CUPERTINO, Calif.—Cellular Biomedicine Group Inc. (CBMG) has completed its newly expanded 30,000-square-foot facility in Huishan High Tech Park in Wuxi, China. An expected 20,000 square feet of the Wuxi GMP facility will be used for advanced stem cell culturing, centralized plasmid and viral vector production, cell banking and reagent development. The company believes that this facility, together with its Zhangjiang Shanghai and Beijing GMP facilities, will be able to support simultaneous clinical trials for five different CAR-T and stem cell products, or have the capacity to treat up to 10,000 cancer and 10,000 knee osteoarthritis patients annually.
 
Tony (Bizuo) Liu, CEO of CBMG, remarked that “We will now be able to centralize, standardize and automate our manufacturing capabilities fully in-house while enhancing our capacity to meet the production demands of multiple products in development as part of our overall chemistry, manufacturing and controls process.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.